Combination of arsenic and interferon-α inhibits expression of KSHV latent transcripts and synergistically improves survival of mice with primary effusion lymphomas.

<h4>Background</h4>Kaposi sarcoma-associated herpesvirus (KSHV) is the etiologic agent of primary effusion lymphomas (PEL). PEL cell lines infected with KSHV, but negative for Epstein-Barr virus have a tumorigenic potential in non-obese diabetic/severe combined immunodeficient mice and r...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hiba El Hajj, Jihane Ali, Akram Ghantous, Dana Hodroj, Ahmad Daher, Kazem Zibara, Chloé Journo, Zaher Otrock, Ghazi Zaatari, Renaud Mahieux, Marwan El Sabban, Ali Bazarbachi, Raghida Abou Merhi
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2013
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/82a3ce35772b42f6be4136d67223f89e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:82a3ce35772b42f6be4136d67223f89e
record_format	dspace
spelling	oai:doaj.org-article:82a3ce35772b42f6be4136d67223f89e2021-11-18T08:47:44ZCombination of arsenic and interferon-α inhibits expression of KSHV latent transcripts and synergistically improves survival of mice with primary effusion lymphomas.1932-620310.1371/journal.pone.0079474https://doaj.org/article/82a3ce35772b42f6be4136d67223f89e2013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24250827/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Kaposi sarcoma-associated herpesvirus (KSHV) is the etiologic agent of primary effusion lymphomas (PEL). PEL cell lines infected with KSHV, but negative for Epstein-Barr virus have a tumorigenic potential in non-obese diabetic/severe combined immunodeficient mice and result in efficient engraftment and formation of malignant ascites with notable abdominal distension, consistent with the clinical manifestations of PEL in humans.<h4>Methodology/principal findings</h4>Using this preclinical mouse model, we demonstrate that the combination of arsenic trioxide and interferon-alpha (IFN) inhibits proliferation, induces apoptosis and downregulates the latent viral transcripts LANA-1, v-FLIP and v-Cyc in PEL cells derived from malignant ascites. Furthermore, this combination decreases the peritoneal volume and synergistically increases survival of PEL mice.<h4>Conclusion/significance</h4>These results provide a promising rationale for the therapeutic use of arsenic/IFN in PEL patients.Hiba El HajjJihane AliAkram GhantousDana HodrojAhmad DaherKazem ZibaraChloé JournoZaher OtrockGhazi ZaatariRenaud MahieuxMarwan El SabbanAli BazarbachiRaghida Abou MerhiPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 11, p e79474 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Hiba El Hajj Jihane Ali Akram Ghantous Dana Hodroj Ahmad Daher Kazem Zibara Chloé Journo Zaher Otrock Ghazi Zaatari Renaud Mahieux Marwan El Sabban Ali Bazarbachi Raghida Abou Merhi Combination of arsenic and interferon-α inhibits expression of KSHV latent transcripts and synergistically improves survival of mice with primary effusion lymphomas.
description	<h4>Background</h4>Kaposi sarcoma-associated herpesvirus (KSHV) is the etiologic agent of primary effusion lymphomas (PEL). PEL cell lines infected with KSHV, but negative for Epstein-Barr virus have a tumorigenic potential in non-obese diabetic/severe combined immunodeficient mice and result in efficient engraftment and formation of malignant ascites with notable abdominal distension, consistent with the clinical manifestations of PEL in humans.<h4>Methodology/principal findings</h4>Using this preclinical mouse model, we demonstrate that the combination of arsenic trioxide and interferon-alpha (IFN) inhibits proliferation, induces apoptosis and downregulates the latent viral transcripts LANA-1, v-FLIP and v-Cyc in PEL cells derived from malignant ascites. Furthermore, this combination decreases the peritoneal volume and synergistically increases survival of PEL mice.<h4>Conclusion/significance</h4>These results provide a promising rationale for the therapeutic use of arsenic/IFN in PEL patients.
format	article
author	Hiba El Hajj Jihane Ali Akram Ghantous Dana Hodroj Ahmad Daher Kazem Zibara Chloé Journo Zaher Otrock Ghazi Zaatari Renaud Mahieux Marwan El Sabban Ali Bazarbachi Raghida Abou Merhi
author_facet	Hiba El Hajj Jihane Ali Akram Ghantous Dana Hodroj Ahmad Daher Kazem Zibara Chloé Journo Zaher Otrock Ghazi Zaatari Renaud Mahieux Marwan El Sabban Ali Bazarbachi Raghida Abou Merhi
author_sort	Hiba El Hajj
title	Combination of arsenic and interferon-α inhibits expression of KSHV latent transcripts and synergistically improves survival of mice with primary effusion lymphomas.
title_short	Combination of arsenic and interferon-α inhibits expression of KSHV latent transcripts and synergistically improves survival of mice with primary effusion lymphomas.
title_full	Combination of arsenic and interferon-α inhibits expression of KSHV latent transcripts and synergistically improves survival of mice with primary effusion lymphomas.
title_fullStr	Combination of arsenic and interferon-α inhibits expression of KSHV latent transcripts and synergistically improves survival of mice with primary effusion lymphomas.
title_full_unstemmed	Combination of arsenic and interferon-α inhibits expression of KSHV latent transcripts and synergistically improves survival of mice with primary effusion lymphomas.
title_sort	combination of arsenic and interferon-α inhibits expression of kshv latent transcripts and synergistically improves survival of mice with primary effusion lymphomas.
publisher	Public Library of Science (PLoS)
publishDate	2013
url	https://doaj.org/article/82a3ce35772b42f6be4136d67223f89e
work_keys_str_mv	AT hibaelhajj combinationofarsenicandinterferonainhibitsexpressionofkshvlatenttranscriptsandsynergisticallyimprovessurvivalofmicewithprimaryeffusionlymphomas AT jihaneali combinationofarsenicandinterferonainhibitsexpressionofkshvlatenttranscriptsandsynergisticallyimprovessurvivalofmicewithprimaryeffusionlymphomas AT akramghantous combinationofarsenicandinterferonainhibitsexpressionofkshvlatenttranscriptsandsynergisticallyimprovessurvivalofmicewithprimaryeffusionlymphomas AT danahodroj combinationofarsenicandinterferonainhibitsexpressionofkshvlatenttranscriptsandsynergisticallyimprovessurvivalofmicewithprimaryeffusionlymphomas AT ahmaddaher combinationofarsenicandinterferonainhibitsexpressionofkshvlatenttranscriptsandsynergisticallyimprovessurvivalofmicewithprimaryeffusionlymphomas AT kazemzibara combinationofarsenicandinterferonainhibitsexpressionofkshvlatenttranscriptsandsynergisticallyimprovessurvivalofmicewithprimaryeffusionlymphomas AT chloejourno combinationofarsenicandinterferonainhibitsexpressionofkshvlatenttranscriptsandsynergisticallyimprovessurvivalofmicewithprimaryeffusionlymphomas AT zaherotrock combinationofarsenicandinterferonainhibitsexpressionofkshvlatenttranscriptsandsynergisticallyimprovessurvivalofmicewithprimaryeffusionlymphomas AT ghazizaatari combinationofarsenicandinterferonainhibitsexpressionofkshvlatenttranscriptsandsynergisticallyimprovessurvivalofmicewithprimaryeffusionlymphomas AT renaudmahieux combinationofarsenicandinterferonainhibitsexpressionofkshvlatenttranscriptsandsynergisticallyimprovessurvivalofmicewithprimaryeffusionlymphomas AT marwanelsabban combinationofarsenicandinterferonainhibitsexpressionofkshvlatenttranscriptsandsynergisticallyimprovessurvivalofmicewithprimaryeffusionlymphomas AT alibazarbachi combinationofarsenicandinterferonainhibitsexpressionofkshvlatenttranscriptsandsynergisticallyimprovessurvivalofmicewithprimaryeffusionlymphomas AT raghidaaboumerhi combinationofarsenicandinterferonainhibitsexpressionofkshvlatenttranscriptsandsynergisticallyimprovessurvivalofmicewithprimaryeffusionlymphomas
_version_	1718421331566919680

Combination of arsenic and interferon-α inhibits expression of KSHV latent transcripts and synergistically improves survival of mice with primary effusion lymphomas.

Ejemplares similares